Analysts' Actions: AXP BMY DO JPM STJ

NEW YORK (TheStreet) -- CHANGE IN RATINGS

American Express (AXP) was upgraded at Morgan Stanley to overweight. Twelve-month price target is $100. OptBlue should drive growth, and the company should see strong spending volume, Morgan Stanley said.

Bristol-Myers (BMY) was upgraded at BMO Capital to outperform from market perform. Twelve-month price target is $60. Immuno-oncology pipeline should drive growth in the coming quarters, BMO Capital said.

Bristow (BRS) was upgraded at William Blair to outperform from market perform. Valuation call, William Blair said.

Cinemark (CNK) was upgraded at J.P. Morgan to overweight from neutral. Stock has overreacted to the company's Latin America exposure, J.P. Morgan said.

Commvault (CVLT) was upgraded to outperform from market perform, JMP Securities said. Twelve-month price target is $80. Survey suggests that customers will spend more this year, JMP Securities said.

Diamond Offshore (DO) was upgraded at FBR Capital Markets to market perform from underperform. Valuation call, based on a 12-month price target of $45, FBR Capital Markets said.

FMC Technologies (FTI) was downgraded at William Blair to market perform from outperform. Company lacks near-term catalysts, William Blair said.

Synageva (GEVA) was upgraded at J.P. Morgan to overweight from neutral. Twelve-month price target is $110. Sebelipase alfa should be the company's next big catalyst, J.P. Morgan said.

Ingram Micro (IM) was upgraded at Brean Capital to buy from hold. Twelve-month price target is $31. Demand is stabilizing and the company is restoring profitability in key regions, Brean Capital said.

JPMorgan Chase (JPM) was upgraded at Societe Generale to buy from hold. Twelve-month price target is $66. Company will likely settle mortgage litigation, and the loan growth outlook is improving, Societe Generale said.

LabCorp (LH) was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $98. Latest guidance suggest that earnings will likely improve from here, Deutsche Bank said.

Cheniere (LNG) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $50. Stock has pulled back to an attractive level, Credit Suisse said.

MDC (MDC) was downgraded at Credit Suisse to neutral from outperform. Twelve-month price target is $30. Spec construction will weigh on margins, Credit Suisse said.

National Fuel Gas (NFG) was downgraded at BMO Capital to market perform. Valuation call, based on a $75 price target, BMO Capital said.

The New York Times Company (NYT) was upgraded to buy at TheStreet Ratings.

U.S. Silica (SLCA) was upgraded at Wells Fargo to outperform. Stock has pulled back to an attractive entry point, Wells Fargo said.

SBA Communications (SBAC) was downgraded at Citigroup to neutral. Valuation call, Citigroup said.

St. Jude (STJ) was upgraded at William Blair to outperform. New product portfolio should drive growth in the coming quarters, William Blair said.

St. Jude was upgraded at Stifel Nicolaus to buy from hold. Twelve-month price target is $75. Company can show accelerating sales growth and expanding margins, Stifel Nicolaus said.

Urban Outfitters (URBN) was upgraded at Brean Murray to buy from hold. Twelve-month price target is $43. Pricing survey and store tours suggest the company is turning the corner, Brean Murray said.


Stock Comments / EPS Changes

ADT (ADT) estimates, price target were cut at Credit Suisse. Shares are now seen reaching $42. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating.

Buckeye Partners (BPL) 12-month price target was raised at UBS. Raised to reflect investments in growth projects, UBS said. Twelve-month price target is $76. Buy rating.

CBOE (CBOE) estimates, price target were increased through 2015 at BMO Capital. Company is keeping a tight lid on costs, BMO Capital said. Market Perform rating.

Cigna (CI) price target, EPS estimates were lowered at Jefferies. Driven by elevated MA costs, Jefferies said. Twelve-month price target is $86. Hold rating.

Cigna estimates, price target were reduced at Credit Suisse. Twelve-month price target is now $91. Estimates were also cut, as the company will likely face margin pressure, Credit Suisse said. Outperform rating.

Exelon (EXC) price target, EPS estimates were raised at UBS. Twelve-month price target is $28. Driven by exceptionally strong Boston capacity price data and strong 2014 guidance, UBS said.

Fiserv (FISV) 12-month price target, EPS estimates were lowered at Jefferies. Driven by margin softness with increased business development, Jefferies said. Twelve-month price target is $64. Buy rating.

Moody's (MCO) estimates, 12-month price target was boosted at Benchmark. Price target is now $81. Estimates were also increased, given higher bond issuance activity, Benchmark said. Hold rating.

Owens Corning (OC) price target, EPS estimates were trimmed at Jefferies. Reflects softer roofing demands due to bad weather, Jefferies said. Twelve-month price target is $51. Buy rating.

Omega Healthcare Investors (OHI) 12-month price target, EPS estimates were raised at Jefferies. Solid pipeline to drive spread investing, which will drive earnings growth, Jefferies said. Twelve-month price target is $32. Hold rating.

Olin (OLN) 12-month price target was increased at UBS. Driven by ongoing strength in ammo against increasing weakness in chlorine products, UBS said. Twelve-month price target is $25. Neutral rating.

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

PayPal Wants to Consolidate the World of Rewards Points

PayPal Wants to Consolidate the World of Rewards Points

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Facebook Is Now Labeling, Archiving Political Ads

Facebook Is Now Labeling, Archiving Political Ads

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Complying With Europe's New Data Rules Could Be Costly for Facebook, Google

Complying With Europe's New Data Rules Could Be Costly for Facebook, Google